治疗和延长方案治疗新生血管性年龄相关性黄斑变性的研究情况

Overview of treatment of neovascular age-related macular degeneration by applying treat and extend regimen

摘要:

新生血管性年龄相关性黄斑变性（neovascular age-related macular degeneration，nAMD）是一种以脉络膜新生血管（choroidal neovascularization，CNV）形成为特征的致盲性眼病，抗血管内皮生长因子（vescular endothelial growth factor，VEGF）药物治疗已成为nAMD的一线治疗并在保存、提高视力方面取得明确效果。目前对于抗VEGF药物治疗注药方案尚无定论，国内外主要使用的方案有固定间隔方案、PRN方案及治疗和延长（treat and extend，T & E）方案。近年来，大量研究表明T & E方案在保证患者视觉收益和减少注药次数方面具有优越性，受到较多学者的推荐，但具体注药次数及视觉收益仍需进一步研究。本综述总结了近年来各类抗VEGF药物以T & E方案治疗nAMD的研究情况，希望对临床治疗有一定参考作用。

Abstract:

Neovascular age-related macular degeneration（nAMD） is an ocular disease causing blind，characterized by choroidal neovascularization（CNV）. Anti-vascular endothelial growth factor（VEGF） therapy has become the first-line treatment of nAMD and gains good therapeutic effects on improving and maintaining eyesight. At present，the frequency of anti-VEGF therapy is not unanimous，but main therapeutic strategies at home and abroad contain monthly and bimonthly fixed treatment，PRN regimen，treat and extend（T & E） regimen. In recent years，studies have found that T & E regimen shows the superiority in guaranteeing visual benefits and reducing injections，which is recommended by experts recently. However，the therapeutic effect and frequency still need to be studied. This review summarized the recent updates on T & E regimen among various anti-VEGF agents for the treatment of nAMD，hoping to supply a reference for clinical treatment.